New drug combo for her2-positive advanced breast cancer after prior treatment failure
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug called RC48 combined with chemotherapy for people with HER2-positive advanced breast cancer that has worsened after treatment with a specific type of antibody-drug conjugate (a drug that targets cancer cells). The goal is to see if this new combination can help when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 or older with HER2-positive advanced breast cancer.
- Your cancer has gotten worse after or you could not tolerate a prior treatment with a certain type of targeted therapy (a TOP1i-ADC).
- You have received no more than 3 prior treatments for advanced or metastatic breast cancer.
- You have at least one measurable tumor outside the brain that can be seen on scans.
- You are in good enough health to be up and about (ECOG performance status 0 or 1).
- You have adequate blood counts, liver, and kidney function (your doctor will check this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests RC48, an antibody-drug treatment, for people with advanced breast cancer that cannot be cured or removed, specifically HER2-low (or HER2-ultralow) tumors. It may help by targeting cancer cells with this “HER2-low” trait while limiting spread in the body.
This trial tests a new combination of targeted drugs (Disitamab Vedotin and RC148) against a standard chemotherapy (Abraxane) with or without an immunotherapy drug (Toripalimab) for advanced breast cancer that is HER2-low and hormone receptor-negative. The goal is to see if the new combination works better at shrinking tumors and slowing cancer growth.
This trial tests a combination of two drugs, disitamab vedotin and bevacizumab, for people with a specific type of advanced breast cancer called HER2-low. It is designed for those who have already been treated with a drug called T-DXd and need further options.
This trial is testing a combination of two drugs (RC48 and AK104) as the first treatment for advanced HER2-positive stomach cancer. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests a new combination of drugs (RC48 plus either Avastin or Pyrotinib) for people with HER2-positive breast cancer that has spread and has stopped responding to the drug T-DXd. The goal is to see if these combinations can help shrink tumors and control the cancer longer.
This trial compares two drug combinations for HER2-positive breast cancer that has spread. It tests a newer drug (Disitamab Vedotin + Pyrotinib) against a standard treatment (THP) as a first treatment option.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.